senti-202
senti-202: 1 clinical trial tracked.
senti-202 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about senti-202, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence0 indications · 1 study sponsors
Related indications
No linked indication is available.
Study sponsors
Clinical Trial Registry Records (1)
SENTI-202-101: A Phase 1, Multicenter, Open-Label Study of SENTI-202, a Selective Off-the-Shelf Logic Gated CAR NK Cell Therapy, in Subjects With CD33 and/or FLT3 Expressing Malignancies
Primary endpoint: Safety and tolerability for dose determination of SENTI-202
Interventionalopen21 targetStarted 2024-04Completion 2040-088 sites · Australia, United StatesSenti Biosciences